No Data
No Data
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Why Did Lilly Data for Oral Obesity Drug Boost Structure and Metsera?
Pfizer (PFE.US) facing setbacks in research sparks acquisition speculation, stocks of the new weight loss drug rising sharply.
Pfizer (PFE.US) has stopped the development of the highly anticipated oral weight loss drug Danuglipron. Investors are betting that this setback may prompt Pfizer to seek acquisition trades, leading to a rise in the stock prices of several biotechnology companies developing weight loss drugs on Monday.
Metsera Shares Are Trading Higher After Pfizer Discontinued the Development of Danuglipron.
Wegovy, Zepbound Makers' Stocks Rally as a Weight-loss-drug Competitor Drops Out